Abstract
Is it time to walk the line between overtreating indolent disease and undertreating aggressive disease?
MeSH terms
-
Age Factors
-
Aged
-
Disease Progression
-
Follow-Up Studies
-
Humans
-
Male
-
Middle Aged
-
Prognosis
-
Prostate-Specific Antigen / blood
-
Prostatectomy / trends*
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / diagnosis
-
Prostatic Neoplasms / surgery*
-
Treatment Outcome
Substances
-
Prostate-Specific Antigen